Phase 2 Start~month

Phase 2 Start: A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitu

Indication
Metastatic Non-Small Cell Lung Cancer (NSCLC); Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Other upcoming events for BMY

Phase 3 ReadoutPhase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to So
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitu — BMY Phase 2 Start | BioSniper